深圳市中新赛克科技股份有限公司 2025 年年度报告全文 深圳市中新赛克科技股份有限公司 2025 年年度报告 2026 年 3 月 1 深圳市中新赛克科技股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人王新东、主管会计工作负责人李斌及会计机构负责人（会计 主管人员）彭道义声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及的未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异，敬请投资者注意投资风险。 公司在本报告"第三节 管理层讨论与分析"之"十一 公司未来发展的 展望"中"（四）影响公司发展的主要风险及对策"部分描述了公司未来经 营中可能面临的风险。敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以本次董事会会议召开 日 2026 年 3 月 17 日总 ...

Financial Performance - The company reported a revenue of RMB 1.5 billion for the fiscal year 2025, representing a year-over-year growth of 15%[14] - The net profit for 2025 was RMB 300 million, an increase of 20% compared to the previous year[14] - The company's operating revenue for 2025 was ¥3,238,452,188.86, a decrease of 8.13% compared to ¥3,525,219,809.86 in 2024[19] - Net profit attributable to shareholders for 2025 was ¥51,765,526.25, down 76.67% from ¥221,921,090.96 in 2024[19] - The net cash flow from operating activities for 2025 was ¥152,384,474.02, a decline of 48.86% compared to ¥297,947,582.50 in 2024[19] - Basic earnings per share for 2025 were ¥0.22, a decrease of 76.60% from ¥0.94 in 2024[19] - Total assets at the end of 2025 were ¥4,393,777,904.57, down 11.02% from ¥4,938,201,873.01 at the end of 2024[20] - The net assets attributable to shareholders at the end of 2025 were ¥3,249,371,193.36, a decrease of 7.58% from ¥3,515,980,251.70 at the end of 2024[20] - The company reported a weighted average return on equity of 1.56% for 2025, down from 6.41% in 2024[20] - The company recorded a total of ¥31,262,919.83 in non-recurring gains for 2025, compared to ¥46,358,954.57 in 2024[26] - The company experienced a significant decline in net profit excluding non-recurring items, which was ¥20,502,606.42 for 2025, down 88.32% from ¥175,562,136.39 in 2024[19] Market and User Growth - User data showed a growth in active users by 25%, reaching a total of 2 million users by the end of 2025[14] - Market expansion efforts include entering three new international markets in 2026, targeting a 10% increase in overseas revenue[14] - Future guidance estimates revenue growth of 12-15% for 2026, driven by new product launches and market expansion[14] - The company achieved a 45.30% year-over-year revenue growth in the commercial market, solidifying its global business development foundation[30] - The company ranks second in the global education market and third in the global commercial market for its interactive flat panel (IFPD) products[29] Research and Development - The company plans to invest RMB 200 million in R&D for new product development in 2026, focusing on AI and smart technology[14] - The company is exploring potential acquisitions to enhance its technology portfolio and market presence[14] - The company has established an AI research institute focusing on AI vision, speech recognition, and educational large models, enhancing its technological capabilities in the education sector[72] - The company is developing the Lesson+ application software, which aims to enhance AI-supported teaching processes and improve classroom efficiency[102] - The AI light screen project is in development, focusing on providing an economical smart terminal solution that integrates recording and AI analysis capabilities[103] - The company has invested in the AI smart pupil screen, which is now in mass production, aiming to create a comprehensive product matrix covering various educational scenarios[103] - The number of R&D personnel increased by 2.66% to 501, with the proportion of R&D staff rising to 30.47%[103] - R&D investment increased by 3.80% to ¥177,425,686.18 in 2025, representing 5.48% of operating revenue, up from 4.85% in 2024[104] Product Development and Innovation - The company’s AI smart screen features a 15T computing power platform and local deployment of AI models, enhancing classroom teaching efficiency and quality[35] - The company’s software platform, Lesson+, provides personalized teaching resources and tools, covering the entire teaching process from preparation to feedback[42] - The company’s smart interactive blackboard integrates traditional blackboard functions with digital technology, enabling automatic digitization of traditional writing[33] - The company’s AI classroom analysis platform supports real-time data monitoring and analysis, aiding in educational decision-making[45] - The company’s smart control management platform offers centralized control of connected interactive devices, enhancing smart campus construction[44] - The Honghe AI Classroom Analysis Platform utilizes AI multimodal technology to provide comprehensive automated analysis of teaching behaviors, student interactions, and learning states, generating diagnostic reports and feedback for teaching improvement[46] - The Smart Education Solution integrates interactive teaching hardware and software, supporting the entire teaching process and enhancing teaching efficiency through seamless technology integration[47] - The AI Multimodal Smart Classroom Solution responds to the demand for intelligent teaching, offering features like smart attendance and interactive discussions to enhance classroom engagement[48] Financial Management and Governance - The company has completed a reform of its supervisory structure, transferring the supervisory functions of the supervisory board to the audit committee of the board of directors[145] - The company has established a transparent performance evaluation and incentive mechanism for directors and senior management to enhance management performance[147] - The company actively engages with stakeholders to balance interests and maximize value for society, shareholders, and employees[148] - The company has completed a governance structure optimization, including the election of a new board and supervisory committee, ensuring independence from its controlling shareholders[151] - The company maintains an independent workforce with established labor, personnel management, and compensation systems, ensuring compliance with legal requirements[153] - The company has a clear and independent organizational structure, with distinct operational and office locations separate from controlling shareholders[155] - The company possesses a complete and independent R&D, procurement, production, and sales system, ensuring no reliance on controlling shareholders for business operations[156] Risks and Challenges - The management highlighted risks related to market competition and regulatory changes in the technology sector[4] - The company faces risks related to national education policies, which could impact customer demand and overall business performance[133] - The company is also addressing risks associated with new business expansions that may not meet expectations due to market demand or competitive pressures[134] - The company has a high proportion of overseas revenue, primarily settled in USD and EUR, making it susceptible to exchange rate fluctuations[136] - The company has implemented a foreign exchange management strategy to hedge against exchange rate risks and minimize the impact on performance[136] Employee Management and Compensation - The total number of employees at the end of the reporting period is 1,644, with 1,599 from major subsidiaries and 45 from the parent company[178] - The employee composition includes 397 production personnel, 513 sales personnel, 501 technical personnel, 60 financial personnel, and 173 administrative personnel[178] - The company has established a standardized compensation system to attract, retain, and motivate talent, aligning with industry market salary levels[179] - The compensation system emphasizes job value and performance contribution, enhancing the link between performance and incentives[180] - Additional employee benefits include supplementary medical insurance, meal allowances, communication subsidies, and transportation allowances[180] Strategic Initiatives - The company aims to deepen its global presence and enhance its market share in emerging regions, focusing on localized operations and supply chain integration[124] - The AI-driven strategy will facilitate the intelligent upgrade of all business areas, aiming for a transition from "device intelligence" to "scene intelligence"[125] - The operational strategy includes cost reduction and efficiency improvements through streamlined processes and enhanced supply chain collaboration[131] - The company will leverage its controlling shareholder's advantages to expand innovative integration scenarios and enhance its global market presence[132] Shareholder Relations - The company ensures the protection of investor rights by maintaining open communication and providing timely updates on business performance and investment value[199] - Shareholder meetings utilize a combination of on-site and online voting to safeguard the decision-making rights of minority investors[200] - The company commits to transparent information disclosure, enhancing the granularity and clarity of industry trends and regulatory information for investors[200]

Financial Performance - Total revenue for 2025 was CNY 73.42 billion, a decrease of 1.29% year-on-year[6] - Operating profit reached CNY 1.51 billion, an increase of 163.80% compared to the previous year[6] - Net profit attributable to shareholders was CNY 1.14 billion, up 76.80% year-on-year[6] - Basic earnings per share increased by 77.39% to CNY 2.04[6] - The weighted average return on equity rose by 2.59 percentage points to 6.26%[6] Segment Performance - The distribution segment generated CNY 53.32 billion in revenue, a year-on-year increase of 0.64%[6] - The retail segment (Guoda Pharmacy) reported revenue of CNY 20.98 billion, a decline of 6.16% year-on-year[7] - Guoda Pharmacy's net profit improved to a loss of CNY 0.22 billion, but showed a year-on-year increase of 80.36%[7] Strategic Focus - The company aims to focus on high-quality development and strategic adjustments in 2026[7] Asset Position - The total assets at the end of the reporting period were CNY 49.10 billion, an increase of 3.24% from the beginning of the period[4]

Financial Performance - The company's operating revenue for 2025 reached ¥2,861,841,123.69, a 31.40% increase compared to ¥2,177,940,839.23 in 2024[21]. - Total profit for the period was ¥125,557,074.99, a decrease of 37.66% from ¥201,405,008.54 in 2024[21]. - Net profit attributable to shareholders was ¥132,412,138.67, down 30.13% from ¥189,518,896.19 in 2024[21]. - The net cash flow from operating activities was ¥104,546,671.09, a decline of 47.67% compared to ¥199,794,611.63 in 2024[21]. - Basic earnings per share decreased by 35.37% to ¥0.53 from ¥0.82 in 2024[22]. - The weighted average return on equity fell to 5.08%, down 4.59 percentage points from 9.67% in 2024[22]. - The company's total assets increased by 15.74% to ¥5,774,681,479.45 from ¥4,989,404,883.19 in 2024[21]. - The net assets attributable to shareholders rose by 3.20% to ¥2,646,682,105.35 from ¥2,564,649,586.26 in 2024[21]. - The company reported a significant drop in net profit for the fourth quarter, with a loss of ¥35,209,398.08 compared to profits in previous quarters[24]. Dividend Distribution - The company plans to distribute a cash dividend of 0.16 CNY per share, totaling approximately 39.94 million CNY, which represents 30.16% of the net profit attributable to shareholders for the fiscal year 2025[5]. - The total share capital of the company is 250,115,693 shares, with 249,619,093 shares used as the basis for calculating the dividend after deducting 496,600 shares held in the repurchase account[5]. - The cash dividend amount (including tax) is RMB 39,939,054.88, which accounts for 30.16% of the net profit attributable to ordinary shareholders[181]. - The cumulative cash dividend amount over the last three fiscal years is RMB 243,926,171.63, representing a cash dividend ratio of 94.91% against the average annual net profit of RMB 256,997,500.53[183]. Research and Development - Research and development expenses accounted for 5.28% of operating revenue, a decrease of 0.42 percentage points from 5.70% in 2024[22]. - The company achieved a total R&D investment of ¥151,202,062.29, representing a 21.89% increase compared to the previous year[68]. - The proportion of R&D investment to operating revenue decreased to 5.28%, down from 5.70%[69]. - The company added 22 new invention patents and 11 utility model patents during the reporting period, bringing the total number of invention patents to 290 and utility model patents to 92[66]. - The company has established a high-level professional R&D team, ensuring a strong talent reserve for continuous tracking of cutting-edge biotechnology developments[60]. - The company is committed to high investment in R&D to develop more bio-based new products, promoting significant advancements in biomanufacturing[56]. - The company has successfully integrated AI technology into its operations, enhancing the efficiency of synthetic biology applications and management processes[49]. - The company is focusing on the development of β-alanine production technologies, including engineered strains and extraction methods, supported by multiple patents[63]. Market Position and Strategy - The company has become a global leader in the production of bio-based products, with a focus on amino acids, vitamins, and bio-based materials[37]. - The company holds the largest global market share for L-alanine, produced through a key anaerobic fermentation technology that has reached international leading levels[38]. - The company is positioned in the rapidly growing bio-manufacturing industry, driven by advancements in synthetic biology technology[34]. - The company is actively pursuing international development strategies and deepening strategic cooperation with global top 500 companies[47]. - A strategic cooperation memorandum was signed with Evonik to focus on the research and promotion of bio-based amino acid products[48]. - The company aims to enhance its market competitiveness and profitability by leveraging its mature synthetic biology technology and advanced manufacturing capabilities[136]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2026[151]. Operational Efficiency - The production model combines "sales-driven production" with "reasonable inventory," enhancing operational efficiency[32]. - The company initiated the "SynData Data-Driven Excellence Operation" project to create an integrated smart operation platform, enhancing operational efficiency and decision-making quality[52]. - The company has established a comprehensive approach to talent cultivation, scientific research, and technology innovation through partnerships with research institutions[60]. - The company has implemented measures to maintain independence from its controlling shareholder, including strict operational separation and independent oversight by the board[144]. Risks and Challenges - The company faces risks related to core technology leakage and personnel turnover, which could adversely affect its competitive position in the market[76][77]. - The company is exposed to raw material price fluctuations, which could negatively impact operational performance if not managed effectively[78]. - The company has ongoing projects, including a 60,000-ton amino acid production facility, which must meet performance expectations to avoid profitability risks[80]. - The company benefits from tax incentives as a high-tech enterprise, but changes in tax policies could impact future earnings[81]. - The company is facing potential risks from industry regulations and market competition, particularly in the L-alanine and L-valine sectors[82]. Governance and Management - The board of directors consists of 9 members, including 3 independent directors, ensuring a clear division of powers and responsibilities[142]. - The company has implemented a performance incentive system to enhance employee motivation and innovation, aligning compensation with industry standards[173]. - The company has appointed several independent directors to strengthen governance and oversight, with compensation ranging from 3.33 million CNY to 10.00 million CNY[147]. - The company has seen a significant increase in the number of shares held by its core technology personnel, indicating a commitment to retaining talent[148]. - The company is focused on maintaining a stable leadership team, with key executives' terms extending until at least November 2028[146].

Financial Performance - The company's operating revenue for 2025 was CNY 443,801,561.97, representing a 5.80% increase from CNY 419,462,944.08 in 2024[19]. - Net profit attributable to shareholders for 2025 was CNY 66,611,410.93, a 19.02% increase compared to CNY 55,966,075.49 in 2024[19]. - The net profit after deducting non-recurring gains and losses for 2025 was CNY 55,733,442.87, up 15.45% from CNY 48,274,093.91 in 2024[19]. - Basic and diluted earnings per share for 2025 were CNY 0.38, an increase of 18.75% from CNY 0.32 in 2024[19]. - The company's gross profit margin improved by 3.16 percentage points to 26.65%, with a total gross profit of CNY 118.25 million, up 20.01% year-on-year[76]. - In 2025, the company achieved a revenue of CNY 443.80 million, representing a year-on-year growth of 5.80% driven by increased product sales[74]. - The company's sales volume increased to 7,676.55 tons in 2025, representing a year-on-year growth of 22.22% compared to 6,280.94 tons in 2024[81]. - The production volume for the main business in chemical new materials reached 8,030.59 tons in 2025, up 26.12% from 6,367.52 tons in 2024[81]. Cash Flow and Investments - The net cash flow from operating activities decreased by 45.36% to CNY 76,185,584.07 from CNY 139,428,467.82 in 2024[19]. - The total investment amount for the reporting period was ¥1,563,012,522.73, reflecting a 3.54% increase from ¥1,509,599,407.13 in the previous year[102]. - The net cash outflow from investment activities in 2025 decreased by 76.52% year-on-year, mainly due to the recovery of idle funds for financial management[93]. - The company's cash and cash equivalents decreased by ¥18,737,112.19, improving from a decrease of ¥152,529,899.06 in the previous year[93]. Dividends and Shareholder Returns - The company reported a cash dividend of 1.00 RMB per 10 shares, totaling 174,881,200 shares, with a capital reserve increase of 3 shares for every 10 shares held[6]. - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares (tax included) and a capital reserve increase of 3 shares per 10 shares for the 2024 fiscal year[187]. - The company has a total of 410,597,570.68 RMB in distributable profits, ensuring a stable financial position for future investments[165]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and social responsibility[6]. - The board of directors consists of 9 members, including 3 independent directors, and held 7 meetings during the reporting period[132]. - The company has established a modern corporate governance structure, ensuring clear responsibilities and effective collaboration among the board, management, and shareholders[173]. - The company has implemented a diversified communication channel for investor relations, enhancing the investor communication experience[135]. - The company has a fully independent management structure, ensuring no institutional overlap with the controlling shareholder[137]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through new technologies and research initiatives[6]. - Research and development expenses increased by 17.86% to CNY 15.11 million, reflecting the company's commitment to innovation and collaboration with academic institutions[76]. - The company aims to produce 8,000 tons of aromatic ketones annually, with new production capacity from the first two workshops starting in 2023[63]. - The company has established joint innovation centers with Nanjing University of Technology and Donghua University to strengthen technology absorption and transformation[112]. Market Trends and Demand - The demand for PEEK in China has shown a CAGR of 42.84% from 2012 to 2021, significantly outpacing the global average growth rate[38]. - The global humanoid robot sales are projected to grow from 12,400 units in 2025 to 5,008,100 units by 2035, with an annual growth rate of 82.23%, driving PEEK demand[39]. - The low-altitude economy market is expected to reach 1.5 trillion yuan by 2025 and 3.5 trillion yuan by 2035, with PEEK being a key material in this sector[39]. Risk Management - The company emphasized the importance of risk awareness regarding forward-looking statements in its strategic plans and operational forecasts[6]. - The financial report includes a detailed analysis of potential risks in the company's future development, urging investors to pay attention to these aspects[6]. - The company faces risks of declining gross margins due to intensified market competition and fluctuations in raw material costs, which significantly impact production costs[120]. - To mitigate gross margin volatility, the company has established long-term relationships with key suppliers for better pricing, enhanced brand influence, and implemented strict procurement management procedures[121]. Environmental and Social Responsibility - The company is committed to environmental protection and sustainable development, adhering to relevant regulations for environmental information disclosure[191]. - The company has been recognized as a leading unit in safety production for several consecutive years, receiving multiple awards for environmental protection and safety standards, including the "Specialized, Refined, Distinctive, and Innovative Small Giant Enterprise" title in 2023[192]. - The company actively participates in social responsibility initiatives and collaborates with government departments to support sustainable development in its operational areas[193]. Employee Welfare and Compensation - The company emphasizes a performance-based compensation system to enhance employee motivation and loyalty, integrating various factors such as training and promotion opportunities[163]. - The company has implemented a comprehensive employee welfare system, including full payment of social insurance and housing funds[189]. - The board of directors approved a salary increase for senior management, with an average increase of 12% based on performance metrics[152].

Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 1.00 per 10 shares (including tax), totaling RMB 9,573,750.8 (including tax) based on a total share capital of 95,737,508 shares after accounting for repurchased shares[5]. - The company will increase capital reserves by issuing 4.8 additional shares for every 10 shares held, without issuing bonus shares[5]. - The profit distribution plan has been approved by the board and will be submitted to the shareholders' meeting for review[6]. - The company has not reported any unremedied losses in the parent company[7]. - The company has not reported any special arrangements for corporate governance[8]. - The company has not experienced any changes in its total share capital that would affect the profit distribution plan[5]. Financial Performance - Jiangsu Huahai Chengke New Materials Co., Ltd. reported a significant increase in revenue, achieving a total of RMB 1.2 billion for the fiscal year 2023, representing a year-over-year growth of 15%[18]. - Operating revenue for 2025 reached CNY 458,055,907, representing a 38.12% increase compared to CNY 331,634,930 in 2024[26]. - Total profit for 2025 was CNY 20,058,875, a decrease of 54.21% from CNY 43,809,642 in 2024[26]. - Net profit attributable to shareholders for 2025 was CNY 24,252,132, down 39.47% from CNY 40,063,058 in 2024[26]. - The net cash flow from operating activities significantly increased by 157.90% to CNY 7,676,254 from CNY 2,976,498 in 2024[26]. - The company's total assets grew by 125.17% to CNY 3,158,289,524 from CNY 1,402,647,705 in 2024[26]. - The net assets attributable to shareholders increased by 109.20% to CNY 2,173,747,829 from CNY 1,039,069,276 in 2024[26]. - Basic earnings per share for 2025 decreased by 40.00% to CNY 0.30 from CNY 0.50 in 2024[27]. Research and Development - The company is investing RMB 200 million in R&D for new technologies, focusing on advanced packaging solutions and materials[18]. - R&D expenditure as a percentage of operating revenue rose to 10.93% in 2025, up from 7.96% in 2024[27]. - The company has established a high-end R&D platform covering pilot production, material research, and failure analysis[65]. - The company has developed a series of advanced packaging materials, focusing on critical technology breakthroughs and continuous R&D in product applications, achieving a leading position in the epoxy encapsulation material sector[71]. - The company has developed new products for automotive electronics and photovoltaic components, leveraging its core packaging material technologies to meet market demands[75]. - The company has completed the development of high thermal conductivity and high insulation materials, achieving a thermal conductivity rate greater than 2 W/m.K[93]. Market Expansion and Strategy - Future outlook indicates a projected revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[18]. - Market expansion efforts include entering three new international markets, aiming for a 10% increase in global market share by the end of 2024[18]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential mergers[196]. - The company plans to accelerate international expansion and increase market share in overseas premium markets, leveraging its established relationships with global semiconductor clients such as Nexperia and Texas Instruments[178]. Risks and Challenges - The company has described potential risks in the "Management Discussion and Analysis" section, urging investors to pay attention to investment risks[3]. - The company faces risks related to the industrialization of advanced packaging materials, which are currently undergoing customer validation and have not yet achieved mass production[107]. - There is a risk of delayed R&D progress, which could impact the timely launch of new products and revenue growth[108]. - The company is exposed to market competition risks, particularly in the high-end semiconductor packaging materials sector[112]. - The product validation cycle is lengthy, which may hinder market expansion if products do not align with customer requirements[111]. Corporate Governance - The company has not violated decision-making procedures for external guarantees[8]. - The company has established a strong sales network, particularly in East China, Southwest China, and South China, with plans for overseas expansion through a newly established subsidiary[43]. - The company has a strategic committee, audit committee, nomination committee, and compensation committee to support effective decision-making processes within the board[186]. - The company has committed to enhancing its governance structure to protect the interests of minority shareholders and ensure compliance with corporate governance standards[184]. Shareholder and Management Changes - 韩江龙, Chairman and General Manager, increased his shareholding by 12,000 shares due to equity incentives, ending the period with 11,253,799 shares[194]. - 成兴明, Director and Deputy General Manager, also increased his shareholding by 12,000 shares, totaling 3,243,515 shares at the end of the period[194]. - The total number of shares held by directors and senior management at the end of the period was 18,363,800 shares, reflecting a decrease of 24,999 shares[195]. - The total pre-tax compensation for directors and senior management amounted to 616.12 million yuan during the reporting period[195]. Operational Efficiency - The company has implemented cost-reduction strategies that are expected to lower operational costs by 5% in the upcoming year[18]. - The company is focusing on enhancing operational efficiency by optimizing supply chain management and production lines, which is expected to lower production costs and improve profit margins[180]. - The company is actively integrating digital management systems, enhancing operational efficiency and reducing labor costs[67]. Product Development and Innovation - The company has developed a new epoxy resin system that improves yellowing resistance and high-temperature aging performance, achieving a reflection rate retention of over 50% after 1000 hours at 150 degrees Celsius[98]. - The company has completed the development of a new epoxy molding compound that addresses cracking issues, improving product reliability through optimized raw materials and high-performance additives[101]. - The company is focusing on developing epoxy molding compounds suitable for storage semiconductor devices in response to the rising demand from AI and high-performance computing markets[84].

江苏浩欧博生物医药股份有限公司2025 年年度报告 公司代码：688656 公司简称：浩欧博 江苏浩欧博生物医药股份有限公司 2025 年年度报告 1 / 277 江苏浩欧博生物医药股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司上市时未盈利且尚未实现盈利 □是 √否 三、重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险，敬请查阅本 报告第三节"管理层讨论与分析"中"四、风险因素"的相关内容。 四、公司全体董事出席董事会会议。 五、 安永华明会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计 报告。 六、公司负责人JOHN LI、主管会计工作负责人张扬清及会计机构负责人（会计主管 人员）李春丽声明：保证年度报告中财务报告的真实、准确、完整。 七、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 根据有关法律法规及《公司章程》的规定，综合考虑股东利益及公司长远发展， 并结合公司实际情况，经董事会研究决定公司2025年 ...

南京三超新材料股份有限公司 2025 年年度报告全文 南京三超新材料股份有限公司 2025 年年度报告 2026-007 2026 年 3 月 18 日 1 南京三超新材料股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律 责任。 公司负责人柳敬麒、主管会计工作负责人曹虎兵及会计机构负责人(会计 主管人员)钱素娟声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 报告期，公司实现营业收入 22,821.49 万元，同比下降 34.58%，实现归 属上市公司股东净利润-15,906.53 万元，同比下降 12.86%，实现扣非净利 润-16,807.08 万元，同比下降 15.95%。 公司业绩亏损的主要原因：1、报告期内，因市场发生变化，下游需求不 振，公司金刚线订单减少，金刚线产品价格大幅下跌，导致营业收入同比下 滑。2、公司及子公司根据会计准则的要求，基于谨慎性原则对存在可能发生 减值迹象的资 ...

福建万辰食品集团股份有限公司 2025 年年度报告全文 福建万辰食品集团股份有限公司 2025 年年度报告 2026-026 2026 年 3 月 18 日 1 福建万辰食品集团股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律 责任。 公司负责人王丽卿、主管会计工作负责人蔡冬娜及会计机构负责人(会计 主管人员)黄阿榕声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划、盈利预测等前瞻性陈述，不构成公司对广大投资 者的实质承诺，有关风险公司已在本报告中描述，敬请投资者注意投资风险， 理性投资。 公司经本次董事会审议通过的利润分配预案为：以 191,293,385 为基数， 向全体股东每 10 股派发现金红利 8.50 元（含税），送红股 0 股（含税），以 资本公积金向全体股东每 10 股转增 0 股。 2 | 第一节 | 重要提示、目录和释义 2 | | --- | --- | ...

Financial Performance - The company expects a net profit of -112.5 million yuan for the year 2025, representing a year-on-year increase of 56.23% to 70.82% compared to the previous year's net profit of -75 million yuan[5]. - The net profit after deducting non-recurring gains and losses is projected to be -95.82 million yuan, with a year-on-year increase of 66.04% to 79.33% compared to -52.83 million yuan last year[5]. - Basic earnings per share are expected to be -0.83 yuan, compared to -0.44 yuan in the previous year[5]. - The earnings forecast is preliminary and has not been audited by the accounting firm, with final figures to be confirmed in the 2025 annual report[10]. Operational Challenges - The company has faced a decrease in operating income due to concessions made on settlement prices for completed projects to accelerate cash collection[7]. - The company has improved its project acceptance review mechanism, leading to the abandonment of projects with potential risks, contributing to a decline in business volume[8]. - Increased litigation costs have arisen from efforts to recover accounts receivable through legal means[9]. - The company has implemented a personnel streamlining policy, resulting in short-term increases in human resource costs due to severance and transitional expenses[9]. - Asset impairment tests have been conducted, and provisions for potential impairment losses have been made based on prudence[9].